Home › Drug Codes › Q Codes › Q9998 · SELARSDI
Updated July 1st, 2026

SELARSDI Q Code: Q9998

Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for Q9998, effective October 1, 2026: $10.48 per HCPCS billing unit, down 0.5% from $10.529. From CMS's final file.

?
Medicare Payment Limit ?
$10.529
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$10.529
/ HCPCS billing unit · APC 0859
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
8
View NDC crosswalk →
Self-Administered Drug Exclusion 7 Medicare Administrative Contractors list Q9998 as usually self-administered and exclude it from Part B coverage in their jurisdictions. Check the article for your MAC before billing: CGS, First Coast, Noridian (A53032), Noridian (A53033), Novitas, Palmetto, Wellpoint Federal, WPS · All SAD lists →

Drug & Product Overview

HCPCS Descriptor Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg
HCPCS Added Date January 1, 2025
Manufacturer Teva
Route of Administration Intravenous, Subcutaneous
Generic Status Single-Source; Branded
Dosage Type Single-Dose
Dosage Form Injection, Solution

About SELARSDI

Selarsdi is a medication aligned to the HCPCS Q Code: Q9998 for billing, pricing, and reimbursement purposes in the United States. This Immunology medication is administered via the intravenous or subcutaneous routes and manufactured by Teva.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. Showing 5 of 8 NDCs — log in for the full crosswalk.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
51759-0413-32 Ustekinumab-aekn Teva Pharmaceuticals USA, Inc. 45 45 MG / 0.5 ML
51759-0414-32 Ustekinumab-aekn Teva Pharmaceuticals USA, Inc. 90 90 MG / 1 ML
51759-0505-13 Selarsdi Teva Pharmaceuticals USA, Inc. 45 45 MG / 0.5 ML
51759-0505-32 Selarsdi Teva Pharmaceuticals USA, Inc. 45 45 MG / 0.5 ML
51759-0708-13 Selarsdi Teva Pharmaceuticals USA, Inc. 130 130 MG / 26 ML
•••••-••••-•• Log in to view SELARSDI
SELARSDI
SELARSDI
Login to view 3 more NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

SELARSDI Pricing & Reimbursement

Q9998 Private Payer Reimbursement
$43.15 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

Ustekinumab Biosimilar Information:

SELARSDI Approval Date: April 16, 2024

Product Name HCPCS Code Active Ingredient BLA Type
Stelara J3358 Ustekinumab 351(a) Originator Product
Wezlana Q5137 Ustekinumab 351(k) Interchangeable
Wezlana Q5138 Ustekinumab 351(k) Interchangeable
Selarsdi Q9998 Ustekinumab 351(k) Interchangeable
Pyzchiva Q9996 Ustekinumab 351(k) Interchangeable
Pyzchiva Q9997 Ustekinumab 351(k) Interchangeable
Otulfi Q9999 Ustekinumab 351(k) Interchangeable
Imuldosa Q5098 Ustekinumab 351(k) Interchangeable
Yesintek Q5100 Ustekinumab 351(k) Interchangeable
Steqeyma Q5099 Ustekinumab 351(k) Interchangeable
Starjemza Q5164 Ustekinumab 351(k) Interchangeable

SELARSDI CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96372 Login for More Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular Login for More
Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

SELARSDI Medically Unlikely Edits (MUE)

The most billing units of Q9998 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient
520 units / day
= 520 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mg Enter a dose to see how many billing units it is and whether it is under the limit.

SELARSDI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Crohn's Disease Plaque Psoriasis Psoriatic Arthritis Ulcerative Colitis
Drug Class
Interleukin-12 Antagonist [EPC]Interleukin-12 Antagonists [MoA]Interleukin-23 Antagonist [EPC]Interleukin-23 Antagonists [MoA]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there an available SELARSDI billing and coding guide?
Billing and coding information for SELARSDI can be found through Teva. Visit Here →
What are the available SELARSDI patient assistance programs?
SELARSDI patient assistance information can be found through Teva. Visit Here →
Where can I find SELARSDI prescribing information?
SELARSDI prescribing information can be found at the link below. Visit Here →
Where can I find SELARSDI side effect information?
Our team has not identified a source of side effect information for SELARSDI
Does billing SELARSDI require JZ/JW wastage modifiers?
CMS does not include SELARSDI (Q9998) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q9998. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to SELARSDI.

J3358STELARAUstekinumab, for intravenous injection, 1 mgJanssenAdded January 1, 2018Q5098IMULDOSAInjection, ustekinumab-srlf (imuldosa), biosimilar, 1 mgAccordAdded July 1, 2025Q5099STEQEYMAInjection, ustekinumab-stba (steqeyma), biosimilar, 1 mgCelltrion USAAdded July 1, 2025Q5100YESINTEKInjection, ustekinumab-kfce (yesintek), biosimilar, 1 mgBiocon Biologics IncAdded July 1, 2025Q5137WezlanaInjection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mgNuvailaAdded July 1, 2024Q5164StarjemzaInjection, ustekinumab-hmny (starjemza), biosimilar, 1 mgHikmaAdded July 1, 2026J3357STELARAUstekinumab, for subcutaneous injection, 1 mgJanssenAdded January 1, 2011J0139HUMIRAInjection, adalimumab, 1 mgAbbvieAdded January 1, 2025J0717CIMZIAInjection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)UCB PharmaAdded January 1, 2014J1628TREMFYAInjection, guselkumab, 1 mgJanssenAdded January 1, 2019